Won the favor of capital as soon as I boarded Nature!

Article source: Medical Rubik's Cube Pro

Author: Haimer

Tumor immunotherapy is another anti-cancer weapon after radiochemotherapy and targeted therapy, but its therapeutic effect is often affected by the immunosuppressive effect of the tumor microenvironment (TME)

Recently, scientists from George Washington University and other institutions challenged the physical barrier outside the tumor.

DDR1 is a tyrosine protein kinase receptor discovered in recent years.

The researchers focused on the ECM that affects the infiltration of immune cells into tumors.

DDR1 can prevent immune cells from infiltrating tumors (Source: Nature)

The researchers knocked out DDR1 in multiple TNBC mouse models, and the results showed that silencing DDR1 can promote the infiltration of T cells in tumors and inhibit tumor growth

DDR1 can be used as a new target for tumor immunotherapy (Source: Nature)

Based on this new tumor immunosuppressive mechanism, Professor Zhiqiang An, the co-corresponding author of the paper, developed a neutralizing antibody targeting DDR1, which can destroy the arrangement of collagen fibers in ECM, improve immune infiltration and inhibit tumor cell growth

DDR1 antibody can inhibit tumor growth (source: Nature)

In general, this study has discovered an immunosuppressive mechanism, proposed a feasible path for reconfiguring tumor ECM to relieve immunosuppression, and revealed that DDR1 can be used as a new target for tumor immunotherapy

At present, the research patent has been licensed to the biotechnology company Parthenon Therapeutics for subsequent drug development

Note: The original text has been deleted

Reference materials:

[1] Xiujie Sun et al.

[2] Researchers identify molecule that blocks immune cells from entering and killing breast tumors.

[3] Parthenon Therapeutics Raises $65 Million in Series A Funding toAdvance Oncology Programs Aimed at Reprogramming the Tumor Microenvironment.

[4] Shen Bingxiang et al.